---
title: "300759.SZ (300759.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/300759.SZ/news.md"
symbol: "300759.SZ"
name: "300759.SZ"
parent: "https://longbridge.com/en/quote/300759.SZ.md"
datetime: "2026-05-20T22:38:06.203Z"
locales:
  - [en](https://longbridge.com/en/quote/300759.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/300759.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/300759.SZ/news.md)
---

# 300759.SZ (300759.SZ) — Related News

### [Norges Bank increased its holdings in Pharmaron by 254,500 shares at an approximate price of HKD 18.71 per share](https://longbridge.com/en/news/286909835.md)
*2026-05-19T12:11:03.000Z*
> According to the latest information from the Hong Kong Stock Exchange, on May 15th, Norges Bank increased its holdings i

### [Pharmaron's actual controller, Lou Xiaoqiang, has newly pledged 250,000 shares, with a cumulative pledge of 1.7% equity](https://longbridge.com/en/news/285461357.md)
*2026-05-07T00:39:00.000Z*
> Pharmaron announced that the actual controller, Lou Xiaoqiang, has pledged 4.7 million shares and released 4.45 million 

### [Pharmaron: One of the actual controllers, Lou Xiaoqiang, pledged and released part of the shares](https://longbridge.com/en/news/285337782.md)
*2026-05-06T08:29:43.000Z*
> Pharmaron announced that one of its actual controllers, Lou Xiaoqiang, has pledged 4.7 million shares to Huatai Securiti

### [](https://longbridge.com/en/news/285188271.md)
*2026-05-05T10:37:01.000Z*
> According to the Hong Kong Stock Exchange, on April 29, BlackRock's long position in Pharmaron's H shares decreased from

### [Pharmaron's three shareholders plan to reduce their holdings by no more than 28.89 million shares, involving 1.6% of the equity](https://longbridge.com/en/news/285012008.md)
*2026-05-04T00:53:00.000Z*
> Pharmaron announced that three shareholders plan to reduce their holdings by no more than 28.891 million shares, account

### [Goldman Sachs Sticks to Its Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)](https://longbridge.com/en/news/284856975.md)
*2026-05-01T01:05:28.000Z*
> Goldman Sachs has reaffirmed its Buy rating for Pharmaron Beijing Co., Ltd. Class H, setting a price target of HK$29.70.

### [In the shareholder letter of Pharmaron, Kang Cheng and Xin Zhonglong intend to reduce their holdings by a total of no more than 1.5% of the shares](https://longbridge.com/en/news/284760020.md)
*2026-04-30T11:37:04.000Z*
> Pharmaron announced that Xincheng Kangcheng and Xincheng Longcheng plan to reduce their holdings by a total of no more t

### [In "The Big Banks," China International Capital Corporation raised the target price for Pharmaron to 26 yuan, maintaining a "Buy" rating](https://longbridge.com/en/news/284719616.md)
*2026-04-30T07:38:41.000Z*
> Bank of China International raised the target price of Pharmaron to HKD 26, maintaining a "Buy" rating. It is expected t